ArticleJournal of tissue engineering
Adipose mesenchymal stem cell-derived nanovesicles as a therapeutic strategy for oral mucosal regeneration after chemotherapy in a rat model.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced oral mucositis (CIOM) is a debilitating complication with limited therapeutic options. Mesenchymal stem cells (MSCs) promote tissue repair through paracrine signaling, and stem cell-derived nanovesicles (SC-NVs) have emerged as a scalable, cell-free therapeutic alternative. However, the regenerative potential of SC-NVs has not been investigated in the context of CIOM. This study evaluated the regenerative effects of SC-NVs derived from human adipose-derived MSCs (AD MSCs) in vitro assays and a rat CIOM model. Transcriptomic profiling showed enrichment of wound healing and angiogenesis-related genes in AD MSCs. SC-NVs were produced by serial extrusion and characterized by nanoscale size and reproducible protein content. Following intralesional injection, SC-NVs localized to the ulcer bed and remained detectable for up to 5 days. SC-NV treatment enhanced epithelial regeneration, promoted angiogenesis, and reduced inflammatory markers in vitro and in vivo. These findings support SC-NVs as a scalable, cell-free therapeutic platform for CIOM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.